BRAF and metastatic colorectal cancer: Furthermore, in an analysis performed with the IdyllaTM Biocartis platform in two first-line prospective clinical trials (PULSE, POSIBA), RAS and BRAF mutational status was assessed in ctDNA from 178 patients with KRAS exon 2 wild-type metastatic colorectal cancer with a sensitivity of 64.1% and a specificity of 90% [29].